April 1, 2026

In part one of his two-part Pharmaceutical Commerce interview series, Pleio CEO Michael Oleksiw unpacks the hidden barriers to adherence that legacy patient support programs were never built to detect — and makes the case that AI-powered insights are now giving pharma companies a clearer, faster window into why patients actually stop. With oral GLP-1 therapies reshaping the market, the cost of not knowing is growing.

March 31, 2026

Michael Oleksiw, CEO of Pleio, discusses the hidden gap in GLP-1 patient support programs and how to boost GLP-1 adherence.

March 31, 2026

Pleio’s Chief Experience Officer Abby Reynolds, PharmD, joined First Report Managed Care to discuss how emotional readiness shapes outcomes in specialty drug management — and why even clinically appropriate therapies stall when patients aren’t supported before functional demands peak.

March 4, 2026

Peer-to-patient support can improve specialty medication adherence. A partnership between Pleio and Gentry Health Services shows how connecting patients with trained peer supporters helps address emotional barriers like fear, worry, and loneliness. The result: stronger onboarding, higher prescription fill rates, and more engaged patients.

January 26, 2025

Pleio’s Chief Pharmacy Officer Mark Gregory, RPh discusses how oral GLP-1 medication will impact the patient medication journey, highlighting how easier access may improve initiation but not necessarily adherence. He explores how fragmented support, knowledge gaps, and emotional barriers can undermine persistence, and why sustained outcomes will depend on coordinated guidance beyond the prescription.

December 23, 2025

Pleio CEO Michael Oleksiw examines why, despite decades of digital innovation and billions invested, medication adherence remains stuck at 50%. Drawing on analysis of more than 140,000 patient conversations, he explores how the “Underminers” shape patient behavior and why the future of pharma depends on combining AI-driven insight with human connection to create lasting adherence.

FOR MEDIA INQUIRIES PLEASE EMAIL media@pleio.com.

WE PUT PRIVACY FIRST. GOODSTART® IS A FULLY TESTED, HIGHLY RELIABLE, TCPA, SOC 2 TYPE 2 CERTIFIED, AND HIPAA COMPLIANT MEDICATION SUPPORT PROGRAM.

Patient data is strictly used to support patients to take medications as prescribed by their healthcare professional.

CONTACT   |   PRIVACY   |   SUPPLIER CONDUCT   |  CAREERS



© 2025 Pleio, Inc All rights reserved.